Capricor Therapeutics Stock News

Marketing of ThermoGenesis CAR-TXpress product line commences under Corning label. First COVID-19 antibody 10 minute test sales shipped.

Dyne Therapeutics today announced the appointment of pediatric neurologist Francesco Muntoni, FRCPCH, FMedSci, to its Scientific Advisory Board.

The

This virtual gathering of the global biotech industry provides access to partners via BIO One-on-One Partnering and educational resources. Capricor Therapeutics, Inc. (CAPR) is a clinical-stage biote

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).

The panel will include an interactive discussion moderated by Jason McCarthy, Ph.D., Maxim Group Senior Managing Director, Biotechnology. Among the topics to be discussed are how cell therapy can tre

The biotech sector has performed very well in the past several months as the industry works to find a solution to the COVID-19 crises. Pluristem Therapeutics ha

Las acciones de las biotecnológicas estadounidense suman hasta un 30%

Capricor (CAPR) delivered earnings and revenue surprises of 16.67% and -11.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Duchenne Muscular Dystrophy Program-Final Top-Line 12-month Results from Phase II Randomized, Double-blind, Placebo-controlled HOPE-2- Study Demonstrated Improved Performance of.

Company management will host a conference call and webcast with slides to discuss its financial results and provide a general business update at 4:30 p.m. (ET) on the same day. Capricor Therapeutic

-One-Year Results from Randomized, Double-Blind, Placebo-Controlled Study Demonstrate Improved Performance of Upper Limb (PUL) 2.0 (p=0.05)- -First Ever Study in DMD that.

Stocks Analysis by Harry Boxer covering: SPDR S&P 500, Amyris Inc, BioCryst Pharmaceuticals Inc, Cytokinetics Inc. Read Harry Boxer's latest article on Investing.com

Athersys and Mesoblast enroll first patients in Phase II/III placebo controlled COVID-19 ARDS trials. Capricor, Mesoblast and Pluristem make waves with very pro

Investors of micro-cap biotech Capricor (CAPR) were probably raising a glass or two last week, as the stock skyrocketed by 253% in one session. The share price surge came following the release of prom